tivantinib

Known as: c-Met Inhibitor ARQ 197 
An orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity. c-Met inhibitor ARQ 197 binds to the c-Met protein… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
PURPOSE Tivantinib, a MET receptor tyrosine kinase inhibitor, demonstrated increased anticancer activity in preclinical and early… (More)
  • figure 1
  • table 2
  • table 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2013
Highly Cited
2013
The receptor tyrosine kinase c-MET is the high-affinity receptor for the hepatocyte growth factor (HGF). The HGF/c-MET axis is… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2013
Highly Cited
2013
PURPOSE MET, the high-affinity receptor for hepatocyte growth factor, is frequently deregulated in human cancer. Tivantinib… (More)
Is this relevant?
2013
2013
Background:The mesenchymal-epithelial transition factor (MET) receptor is dysregulated in hepatocellular carcinoma (HCC), and… (More)
  • table 1
  • table 2
  • figure 1
Is this relevant?
Review
2013
Review
2013
INTRODUCTION Tivantinib (ARQ 197) is a selective, oral MET receptor tyrosine kinase inhibitor with broad-spectrum antitumor… (More)
  • figure 1
  • figure 2
  • table 1
Is this relevant?
Highly Cited
2012
Highly Cited
2012
We present the rationale and design for MARQUEE, a phase III, randomized, double-blind, placebo-controlled study of ARQ 197 plus… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Microphthalmia transcription factor (MITF)-associated (MiT) tumors are a family of rare malignancies, including… (More)
Is this relevant?
2012
2012
BACKGROUND Amplification of the mesenchymal-epithelial transition factor (MET) gene can promote tumor resistance to epidermal… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
PURPOSE c-MET (MET) receptor activation is associated with poor prognosis and epidermal growth factor receptor (EGFR) tyrosine… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
BACKGROUND Tivantinib, an oral, non-ATP competitive, selective c-MET inhibitor, exhibited antitumor activity in preclinical… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?